Abstract 248P
Background
Many patients concern the body imbalance after mastectomy and it is often cited as justification for immediate-breast reconstruction (IBR). However, few studies have investigated the impact of mastectomy or IBR on scoliosis, and analyzed only a small number of patients. We investigated whether mastectomy impacts spine alignment compared to IBR with a large cohort.
Methods
We retrospectively reviewed the patients who underwent breast cancer surgery between 2004 and 2018 at a single institution. Using the deep learning-based algorithm (DeepNoid Inc.), we collected Cobb's angle from chest posteroanterior x-rays at three time points: pre-operation, postoperative one-year, and five-years. Patients who underwent bilateral surgery, delayed-reconstruction, or LD-flap were excluded.
Results
Totally 6246 patients were included: 3442 (55.1%), 1911 (30.6%), and 893 (14.3%) patients underwent breast-conservation surgery (BCS), mastectomy without IBR, and IBR, respectively. At postoperative five-years, the mastectomy group showed the significantly greater change in Cobb's angle compared to both the BCS (p<0.001) and IBR (p=0.004) groups, while there was no significant difference between the BCS and IBR groups (p=0.347). After adjusting for other clinicopathologic variables, operation methods, adjuvant hormone treatments, and the direction of cancer remained significant factors affecting vertebral alignment. However, there was no relationship between the excised breast weights and Cobb's angle. Propensity score matching also showed that mastectomy group has greater change in angle compared to the other groups (vs. BCS, p=0.041; vs. IBR, p=0.047). Cobb’s angle was more evidence among patients under 50 years old (p=0.016) and who administered hormone treatment (p=0.009). Lastly, significantly more patients experienced lumbar pain after mastectomy (8.4%) than after BCS (6.7%) or IBR (4.1%) during the surveillance (p<0.001).
Conclusions
This is the largest study that showed the significant change in thoracic spine alignment after mastectomy compared to BCS and IBR. The results would provide the evidence on recommending breast reconstruction especially for young patients and educating post-mastectomy postural correction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Seoul National University Hospital.
Disclosure
H. Lee; W. Han: Financial Interests, Personal, Stocks or ownership, Not relevant to this study: DCGen. All other authors have declared no conflicts of interest.
Resources from the same session
1978P - Accurate detection of urothelial carcinoma by whole-genome methylation profiling of urinary cell-free DNA
Presenter: Huiqin Guo
Session: Poster session 13
1979P - Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study
Presenter: Li Zhou
Session: Poster session 13
1980P - Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial
Presenter: Evanguelos Xylinas
Session: Poster session 13
1981P - Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
Presenter: Marco Stellato
Session: Poster session 13
1982P - Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)
Presenter: Begona Perez Valderrama
Session: Poster session 13
1983P - Feasibility and efficacy of split-dose cisplatin with atezolizumab for cisplatin-ineligible urothelial carcinoma (SOGUG-AUREA): Final results
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 13
1984P - Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial
Presenter: Chu Yang
Session: Poster session 13
1985P - Retrospective database analysis of real-world treatment patterns and sequencing in locally advanced or metastatic urothelial carcinoma patients receiving sacituzumab govitecan
Presenter: Ronac Mamtani
Session: Poster session 13
1986P - Prospective evaluation of BCG unresponsive bladder cancer carcinoma in situ identifies genetic mechanisms of immunotherapy resistance and targeted therapy using an ultra-sensitive next generation sequencing minimal residual disease (MRD) assay
Presenter: Joshua Meeks
Session: Poster session 13
1987P - TROP-2 as a promising ADC target in penile squamous cell carcinoma that promotes cell proliferation by activating AKT through PKCα pathway
Presenter: Yi Tang
Session: Poster session 13